MAbMods™ Anti-Mouse CD20 (Clone 18B12) – Biotin

mAbMods™ Anti-Mouse CD20 (Clone 18B12) – Biotin

Product No.: C1044

- -
- -
Product No.C1044
Clone
18B12
Target
CD20
Product Type
Recombinant Monoclonal Antibody for in vivo Use
Alternate Names
MS4A1, Ly-44
Isotype
Mouse IgG2a k
Applications
FA
,
FC
,
IF
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Mouse CD20 transfected cells
Product Concentration
0.5 mg/ml
Formulation
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Additional Applications Reported In Literature ?
B,
FA,
in vivo,
WB,
IHC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
18B12 activity is directed against murine CD20.
Background
This anti-CD20 antibody is a recombinant chimeric version of the original clone 18B12 antibody. The variable domain sequences are identical to the original clone 18B12; however, the constant region sequences have been switched from mouse IgG1 to mouse IgG2a.

CD20 is a phosphoprotein belonging to the MS4A family, with a size of 33-37 kD. It is primarily found on B cells, including malignant B cells. This protein serves as a target, for therapies that aim to deplete B cells using antibodies 1–4. CD20 works alongside surface IgM and plays a role in calcium conductance, cell cycle progression, and B cell growth 5,6. Many B cell malignancies exhibit levels of CD20, which remain on the cell surface after treatment with monoclonal antibodies. This makes it an effective target for antibody-based treatments 7.

Although CD20 is mainly associated with B cells it has also been observed on a subset of T lymphocytes and follicular dendritic cells. However, its function in these cell types is not yet fully understood. CD20-positive T cells have been detected in conditions like autoimmune diseases, cancers, and infections 8,9.

Clone 18B12 is commonly used in research for studying B cell biology and immune responses. Researchers utilize this antibody for applications like flow cytometry analysis, immunohistochemistry studies as well as in vivo investigations using mouse models. By employing this antibody variant scientists have made progress in understanding the role of CD20, in autoimmune diseases, lymphomas, and other disorders related to B cell dysfunction 10–14.
Antigen Distribution
CD20 is a general B cell marker expressed by most normal B cells in all stages of their development and by most B cell malignancies.
Ligand/Receptor
Associates with MHC class I and II, CD53, CD81, and CD82.
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Immunology

References & Citations

1. Middleton O, Wheadon H, Michie A. In: Ratcliffe MJH, ed. Vol 2. Elsevier; 2016. Accessed January 2, 2024.
2. Freeman CL, Sehn LH. Br J Haematol. 2018;182(1):29-45.
3. Shanehbandi D, Majidi J, Kazemi T, Baradaran B, Aghebati-Maleki L. Curr Cancer Drug Targets. 2017;17(5):423-444.
4. Bockenstedt MM, Boggiatto PM, Jones DE. Int J Clin Exp Pathol. 2015;8(6):6192-6202.
5. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. J Cell Biol. 1993;121(5):1121-1132.
6. Boisvert M, Cohen SR. J Pain Symptom Manage. 1995;10(8):632-638.
7. Boross P, Leusen JHW. Am J Cancer Res. 2012;2(6):676-690.
8. Montgomery BL, Franklin KA, Terry MJ, et al. Plant Physiol. 2001;125(1):266-277.
9. Lee AYS. Inflamm Res. 2022;71(10-11):1181-1189.
10. Montalvao F, Garcia Z, Celli S, et al. J Clin Invest. 2013;123(12):5098-5103.
11. Sitaru C, Thiel J. Exp Dermatol. 2014;23(4):236-237.
12. Meffre E, O’Connor KC. Immunol Rev. 2019;292(1):90-101.
13. Kurosaki T. J Clin Invest. 2008;118(10):3260-3263.
14. Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS. Haematologica. 2010;95(1):135-143.
FA
Flow Cytometry
IF
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.